苯丁酸钠-熊去氧胆酰牛磺酸(Relyvrio)。
此药物于 2022 年获得
FDA
的批准,可以将
ALS
患者的功能衰退速度降低约 25%。它也可能有助于延长
ALS
患者的寿命,大约为 6 个月。药物为粉末剂型,溶于室温水中服用。潜在副作用包括腹泻、腹痛、恶心和上呼吸道感染。患者如果患有影响胆汁酸循环的疾病,则可能会发生腹泻,并会在使用此药物时症状恶化。这种药味道不佳。
医务人员也可能会开具缓解其他症状的疗法,包括:
肌肉痛性痉挛和肌痉挛。
唾液和痰分泌过多。
睡眠问题。
忍不住的大笑或哭泣。
腿部肿胀。
疗法
当
ALS
累及您的呼吸、说话和行动能力时,治疗和其他形式的支持可能会有所帮助。
呼吸护理。
随着肌肉不断衰弱,大多数
ALS
患者的呼吸最终会变得更加困难。医务人员可能会定期测试您的呼吸情况,并为您提供辅助夜间呼吸的机械通气设备。
您可以选择使用面罩可轻松取戴的呼吸机,也被称为无创通气。有些患者最终会做手术,在颈部前方开一个通往气管的孔,称为气管造口。插入孔中的管子与呼吸器相连,帮助患者呼吸。有时做了气管造口的
ALS
患者还需要做一种叫做喉切除术的手术。这项手术旨在防止食物进入肺部。
Elman LB, et al. Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
Preston DC, et al. Amyotrophic lateral sclerosis and its variants. In: Electromyography and Neuromuscular Disorders. 4th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Feb. 16, 2023.
Elman LB, et al. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
Goldman L, et al., eds. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Goldman-Cecil Medicine. 26th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Feb. 16, 2023.
Amyotrophic lateral sclerosis (ALS) fact sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet. Accessed Feb. 16, 2023.
Environmental factors. ALS Association. https://www.als.org/research/research-we-fund/scientific-focus-areas/environmental-factors. Accessed Feb. 16, 2023.
After the ALS diagnosis: Coping with the 'new normal.' ALS Association. http://www.alsa.org/als-care/resources/publications-videos/resource-guides/. Accessed Feb. 16, 2023.
Ami TR. Allscripts EPSi. Mayo Clinic. Dec. 22, 2022.
Dharmadasa T, et al. Genetic testing in motor neuron disease. Practical Neurology. 2022; doi:10.1136/practneurol-2021-002989.
Mehta P, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2022; doi:10.1080/21678421.2021.2023190.
Relyvrio (approval letter). New Drug Application 216660. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed Feb. 17, 2023.
Yamakawa M, et al. Demographics, clinical characteristics and prognostic factors of amyotrophic lateral sclerosis in Midwest. Muscle & Nerve. 2022; doi:10.1002/mus.27450.
Van Blitterswijk M, et al. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: Can we learn from other noncoding repeat expansion disorders? Current Opinion in Neurology. 2012; doi:10.1097/WCO.0b013e32835a3efb.
ALS certified centers and clinics. ALS Association. https://www.als.org/local-support/certified-centers-clinics?search_api_fulltext=Mayo+Clinic. Accessed Dec. 8, 2022.
Barry RL, et al. Ultra-high field (7T) functional magnetic resonance imaging in amyotrophic lateral sclerosis: A pilot study. NeuroImage Clinical. 2021; doi:10.1016/j.nicl.2021.102648.
Dorst J, et al. Clinical studies in amyotrophic lateral sclerosis. Current Opinion in Neurology. 2022; doi:10.1097/WCO.0000000000001099.
Oskarsson BE (expert opinion). Mayo Clinic. Jan. 6, 2023.
Sun Y, et al. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics. 2023; doi:10.1080/14737175.2023.2174018.
Sturmey E, et al. Blood biomarkers in ALS: Challenges, applications and novel frontiers. Acta Neurologica Scandinavica. 2022; doi:10.1111/ane.13698.
Soga T, et al. Long-term outcomes after surgery to prevent aspiration for patients with amyotrophic lateral sclerosis. BMC Neurology. 2022; doi:10.1186/s12883-022-02619-z.
Rutkove SB, et al. Differential diagnosis of peripheral nerve and muscle disease. https://www.uptodate.com/contents/search. Accessed March 9, 2023.
National Amyotrophic Lateral Sclerosis (ALS) Registry. Centers for Disease Control and Prevention. https://www.cdc.gov/als/GeneralPublic_AboutRegistry.html. Accessed March 9, 2023.
Johnson SA (expert opinion). Mayo Clinic. March 8, 2023.
Staff NP (expert opinion). Mayo Clinic. March 9, 2023.
Oskarsson BE (expert opinion). Mayo Clinic. Feb. 21, 2023.